抗耐药结核病新药吡法齐明通过醌氧化还原酶介导发挥作用的机制研究

doi:10.3969/j.issn.1000-6621.2021.06.010

摘要/Abstract

摘要：

目的对吡法齐明(pyrifazimine,TBI-166)通过醌氧化还原酶(quinone oxidoreductase,QOR)介导累积活性氧(reactive oxygen species,ROS)发挥抗结核作用的机制进行探索。方法表达、纯化MtbQOR蛋白,设置空白对照组及加TBI-166(0.03、0.3、3μg/ml)组,酶标仪监测波长340nm处吸光度(A_{340 nm})下NADPH的下降程度(ΔA);应用辅酶Ⅱ NADP(H)含量检测试剂盒检测不同浓度TBI-166作用H37Rv菌体后NADPH/NADP⁺的比值;应用细菌活性氧检测试剂盒检测结核分枝杆菌H37Rv标准株和临床分离株菌体内ROS荧光值。结果空白对照组ΔA(0.316±0.032)较0.03、0.3、3μg/ml TBI-166组 (0.506±0.107、0.531±0.054、0.801±0.079)明显降低,差异有统计学意义(t=-3.799,P<0.05;t=-7.634,P<0.01;t=-12.683,P<0.01)。在48h内,加TBI-166组NADPH/NADP⁺比值(0.847±0.229)低于空白对照组比值(1.728±0.384)。H37Rv菌株中,TBI-166刺激组ROS荧光值(23072±2584)明显高于空白对照组(8282±448),差异有统计学意义(F=33.334,P<0.01)。在菌株号为12897菌株中,TBI-166刺激组ROS荧光值(18369±3118)明显高于空白对照组(12268±2735),差异有统计学意义(F=5.026,P<0.05);在菌株号为15171菌株中,3μg/ml TBI-166刺激组ROS荧光值(17572±249)明显高于空白对照组(11109±343),差异有统计学意义(F=122.601,P<0.01);在菌株号为11492及11195菌株中,TBI-166刺激组与空白对照组ROS荧光值差异无统计学意义(F=161.440,P>0.05;F=44.788,P>0.05)。结论 TBI-166可以通过增加MtbQOR介导的氧化还原反应,降低NADPH/NADP⁺的比值,刺激菌体累积ROS发挥抗结核作用。

关键词: 分枝杆菌,结核, 药理作用分子机制, 醌氧化还原酶, 吡法齐明

Abstract:

Objective To study the mechanism of pyrifazimine (TBI-166) accumulating reactive oxygen species (ROS) to kill Mycobacterium tuberculosis(MTB) through quinone oxidoReductase (QOR). Methods MtbQOR protein was expressed and purified. The decrease of NADPH (ΔA) at A_{340 nm} in blank control group and TBI-166 (0.03、0.3、3μg/ml) groups were detected by microplate reader; NADPH/NADP⁺ ratio of H37Rv after exposure to TBI-166 of different concentrations were detected by coenzyme Ⅱ NADP (H) detection kit; ROS fluorescence value of H37Rv strains and clinical collected strains were tested by bacterial ROS detection kit. Results The ΔA of control group (0.316±0.032) was lower than that of 0.03, 0.3, 3μg/ml TBI-166 groups (0.506±0.107, 0.531±0.054, 0.801±0.079) (t=-3.799,P<0.05;t=-7.634,P<0.01;t=-12.683,P<0.01). Within 48 hours, the NADPH/NADP⁺ratio of TBI-166 groups (0.847±0.229) was lower than that of the control group (1.728±0.384). ROS fluorescence value of H37Rv strains in TBI-166 groups (23072±2584) was higher than that of the control group (8282±448) (F=33.334, P<0.01). ROS fluorescence value of the strain number 12897 in TBI-166 groups (18369±3118) was higher than that of the control group (12268±2735) (F=5.026, P<0.05). ROS fluorescence value of the strain number 15171 in 3μg/ml TBI-166 group (17572±249) was higher than that of the control group (11109±343)(F=122.601, P<0.01). There was no significant difference detected in ROS fluorescence value between TBI-166 groups and blank control group in the strains numbered 11492 and 11195 (F=161.440, P>0.05; F=44.788, P>0.05). Conclusion TBI-166 could enhance redox reaction mediated by MtbQOR, decrease the ratio of NADPH/NADP⁺ and accumulate intra-bacterial ROS to kill MTB.

Key words: Mycobacterium tuberculosis, Molecular mechanism of pharmacological action, Quinone oxidoreductase, TBI-166

张蕾, 李媛媛, 陈曦, 刘海婷, 徐建, 王宁, 丁杨明, 陆宇. 抗耐药结核病新药吡法齐明通过醌氧化还原酶介导发挥作用的机制研究[J]. 中国防痨杂志, 2021, 43(6): 576-583. doi: 10.3969/j.issn.1000-6621.2021.06.010

ZHANG Lei, LI Yuan-yuan, CHEN Xi, LIU Hai-ting, XU Jian, WANG Ning, DING Yang-ming, LU Yu. Study of the mechanism of the new antidrug-resistant tuberculosis drug pyrifazimine mediated by quinone oxidoreductase[J]. Chinese Journal of Antituberculosis, 2021, 43(6): 576-583. doi: 10.3969/j.issn.1000-6621.2021.06.010

图/表 8

图1

图2

图3

图4

图5

图6

图7

图8

参考文献 19

[1]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[2]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020,382(10):893-902. doi: 10.1056/NEJMoa1901814. doi: 10.1056/NEJMoa1901814 URL
[3]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
[4]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006
[5]	Lu Y, Zheng M, Wang B, et al. Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation. Antimicrobial Agents and Chemotherapy, 2011,55(11):5185-5193. doi: 10.1128/AAC.00699-11. doi: 10.1128/AAC.00699-11 URL
[6]	张叶, 李媛媛, 徐建, 等. 吡法齐明抗耐药结核分枝杆菌作用机制的初步研究. 中国防痨杂志, 2019,41(11):1160-1166. doi: 10.3969/j.issn.1000-6621.2019.11.004. doi: 10.3969/j.issn.1000-6621.2019.11.004
[7]	Rao PV, Krishna CM, Zigler JJ. Identification and characterization of the enzymatic activity of zeta-crystallin from guinea pig lens. A novel NADPH:quinone oxidoreductase. J Biol Chem, 1992,267(1):96-102. pmid: 1370456
[8]	Zheng Q, Song Y, Zhang W, et al. Structural views of quinone oxidoreductase from Mycobacterium tuberculosis reveal large conformational changes induced by the co-factor. FEBS J, 2015,282(14):2697-2707. doi: 10.1111/febs.13312. doi: 10.1111/febs.13312 URL
[9]	Makafe GG, Hussain M, Surineni G, et al. Quinoline Derivatives Kill Mycobacterium tuberculosis by Activating Glutamate Kinase. Cell Chem Biol, 2019,26(8):1187-1194. doi: 10.1016/j.chembiol.2019.05.003. doi: 10.1016/j.chembiol.2019.05.003 URL
[10]	Xu J, Wang B, Fu L, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019,63(5):e02155-18. doi: 10.1128/AAC.02155-18. doi: 10.1128/AAC.02155-18
[11]	李聃, 盛莉, 赵曼曼, 等. 新型抗结核化合物TBI-166在比格犬体内的生物利用度. 国际药学研究杂志, 2015,42(2):194-198. doi: 10.13220/j.cnki.jipr.2015.02.013. doi: 10.13220/j.cnki.jipr.2015.02.013
[12]	Zhang Y, Zhu H, Fu L, et al. Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo. Antimicrob Agents Chemother, 2019,63(7):e02496-18. doi: 10.1128/AAC.02496-18. doi: 10.1128/AAC.02496-18
[13]	Zhu H, Fu L, Wang B, et al. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother, 2021,65(4):e02164-20. doi: 10.1128/AAC.02164-20. doi: 10.1128/AAC.02164-20
[14]	Bolton JL, Trush MA, Penning TM, et al. Role of quinones in toxicology. Chem Res Toxicol, 2000,13(3):135-160. doi: 10.1021/tx9902082. doi: 10.1021/tx9902082 pmid: 10725110
[15]	Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem, 2011,286(12):10276-10287. doi: 10.1074/jbc.M110.200501. doi: 10.1074/jbc.M110.200501 URL
[16]	张姗姗, 王彦, 李德东, 等. NADH和NADPH代谢和功能的研究进展. 第二军医大学学报, 2011,32(11):1239-1243. doi: 10.3724/SP.J.1008.2011.01239. doi: 10.3724/SP.J.1008.2011.01239
[17]	Lee EH, Baek SY, Park JY, et al. Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling. Chem Biol Interact, 2020,315:108889. doi: 10.1016/j.cbi.2019.108889. doi: 10.1016/j.cbi.2019.108889 URL
[18]	Islam MM, Hameed H, Mugweru J, et al. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J Genet Genomics, 2017,44(1):21-37. doi: 10.1016/j.jgg.2016.10.002. doi: 10.1016/j.jgg.2016.10.002 URL
[19]	Yang S, Lian G. ROS and diseases: role in metabolism and energy supply. Mol Cell Biochem, 2020,467(1/2):1-12. doi: 10.1007/s11010-019-03667-9. doi: 10.1007/s11010-019-03667-9 URL